Q-omics provides the consensus-scored TTLL13P profile across patient tissues and cancer cell-line models. TTLL13P expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TTLL13P is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TTLL13P RNA expression shows 16,843 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where TTLL13P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTLL13P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTLL13P survival associations across molecular data types. TTLL13P RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTLL13P RNA expression–survival associations across cancer types. High TTLL13P expression shows unfavorable associations in KIRC, UCS and ESCA, but favorable associations in MESO, BLCA and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TTLL13P RNA expression.
This table summarizes TTLL13P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TTLL13P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTLL13P shows higher tumor expression in HNSC, BLCA, BRCA, KIRP, LIHC and CHOL. The HNSC box plot shows higher TTLL13P RNA expression in tumor versus normal tissue (log2 FC = +0.099, t-test p < 0.001).
This table shows molecular features associated with TTLL13P in patient tissues and cancer cell lines. In patient samples, TTLL13P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTLL13P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
